Anti-CRISPR (Acr) proteins are bacteriophage-derived antagonists of CRISPR-Cas systems. To date, Acrs were obtained either by mining sequence databanks or experimentally screening phage collections, both of which yield a limited repertoire of naturally occurring variants. Here, we applied structure-based engineering on AcrIIC1, a broad-spectrum inhibitor of type II-C CRISPR systems, to improve its efficacy and expand its specificity. We first show that fusing exogenous protein domains into AcrIIC1 dramatically enhances inhibition of the natural Neisseria meningitidis Cas9 target. Then, using structure-guided design, we converted AcrIIC1 into AcrX, a potent inhibitor of the type II-A CRISPR-Cas9 from Staphylococcus aureus widely applied for in vivo genome editing. Our work introduces designer Acrs as important biotechnological tools and provides an innovative strategy to safeguard the CRISPR technology.The detailed characterization of bacterial CRISPR-Cas systems 1 and their adaptation for precise genome engineering in mammalian cells 2, 3 has revolutionized the life sciences and enabled novel applications in biotechnology and medicine. The recent discovery of phage-derived anti-CRISPR proteins 4-6 , i.e. potent inhibitors of Cas effectors, provides a shut-off mechanism that can keep this powerful technology in check 7 and enhance the precision at which genome perturbations can be made [8][9][10][11] . While mining of sequence databases and screening of phage libraries proved to be powerful strategies to discover Acrs targeting a variety of Cas effectors 5, 6, 12-18 , these approaches are inherently limited to the naturally occurring protein sequence space. Moreover, for various Cas effectors of major biotechnological interest, nature might be lacking (efficient) anti-CRISPR counterparts.